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Special issue: Molecular basis of NCLThe neuronal ceroid lipofuscinoses (NCL), also known as
Batten disease, are a group of rare and devastating neurode-
generative disorders that can strike at any age, from before birth
up to late in life. They are inherited, usually in an autosomal
recessive manner, and at present are incurable, with no
treatment even to halt disease progression.
This special issue was initiated by the NCL Foundation of
Germany and arises from the last international meeting on the
NCLs—the 10th international congress, NCL-2005—which
was held in Helsinki, Finland, and attended by experts from
around the world, and comprises a series of reviews. One review
(Haltia) deliberately looks to the past, so that relevant knowl-
edge and experience in an increasingly molecular age are not
forgotten, but most look forward as progress is made in
understanding the molecular basis of the NCLs. The majority of
reviews are deliberately co-authored to reflect the cooperative
international expertise that exists, a particular feature perhaps of
research into a rare disease that is still such a challenge to
understand. The aim of these reviews is to provide articles that
summarise the current status of the NCL field.
The molecular basis for the NCLs is not fully understood.
This collection of diseases was first recognised as a separate
group in the 1960s, and is now known to cover disease caused
by mutations in seven human genes, with more expected to
exist. Mutations in many of these genes may be severe to mild,
resulting in a range of ages of onset and rates of disease
progression, and even disease of a very different clinical course
(Siintola et al.). The diagnosis of NCL is on the verge of a small
revolution as more genes are identified, and the variety of
disease phenotypes is expanding, making this a challenging area
for clinicians faced with diagnosis of such a rare disease, albeit
with some common forms (Williams et al.). Mutations in other
genes cause NCL or NCL-like disease in animals. One recent
focus of research has been to identify animal models for each
NCL disease, both small (Cooper et al.) and large (Tammen et
al. and Houweling et al.) and to study these to understand the
disease itself (Jalanko et al.). Future work will increasingly use
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doi:10.1016/j.bbadis.2006.10.005Dawson). Another recent focus has been the development of
simple model systems (Pearce et al.) as well as studying
mammalian cells (Kyttala et al.) to better understand the
function and the cell biology of each NCL gene. Keeping up
with progress in clinical, research, professional advances and
support for families in the NCL field is a challenge, but
fortunately Internet access to clinical and scientific publications
and the many web sites containing useful information has made
this easier for all concerned.
The future looks brighter for the NCLs, more than a hundred
years after they were first described, than it did several decades
ago. Whilst this issue cannot include all aspects and details of
the NCLs, it is hoped that these articles will provide good
summaries for those new to the field, as well as bringing
together important features for those more familiar, and perhaps
making succinct predictions about future hopes. A cure for NCL
does not yet exist, but work leading towards this is in place and
being done. Progress will continue to be reported at biennial
international meetings, the next one being held in Rochester,
New York, USA, in July 2007.
Sara E. Mole
MRC Laboratory for Molecular Cell Biology and
Departments of Paediatrics & Child Health and Biology,
University College London, London WC1E 6BT, UK
E-mail address: s.mole@ucl.ac.uk
Corresponding author.
Glyn Dawson
Department of Pediatrics, Biochemistry & Molecular Biology,
University of Chicago, Chicago, IL 60637, USA
E-mail address: dawg@uchicago.edu
Anu Jalanko
National Public Health Institute,
Department of Molecular Medicine,
Biomedicum Helsinki, POB 104, 00251 Helsinki, Finland
E-mail address: anu.jalanko@ktl.fin
